Empowered Funds LLC Cuts Stock Position in XBiotech Inc. (NASDAQ:XBIT)

Empowered Funds LLC lessened its holdings in XBiotech Inc. (NASDAQ:XBIT) by 9.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,551 shares of the biopharmaceutical company’s stock after selling 6,586 shares during the quarter. Empowered Funds LLC owned 0.21% of XBiotech worth $484,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in XBiotech by 1.6% during the first quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company’s stock worth $7,279,000 after acquiring an additional 13,804 shares during the period. Rhumbline Advisers grew its stake in shares of XBiotech by 2,568.5% during the 2nd quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 19,341 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of XBiotech by 102.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 49,863 shares in the last quarter. Finally, American Century Companies Inc. acquired a new position in XBiotech during the second quarter worth about $393,000. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Price Performance

XBIT stock opened at $6.83 on Monday. XBiotech Inc. has a 12 month low of $3.54 and a 12 month high of $9.96. The firm has a market capitalization of $208.18 million, a PE ratio of -6.32 and a beta of 1.42. The company’s 50 day simple moving average is $7.22 and its 200-day simple moving average is $6.88.

XBiotech Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.